Table 2.
Tumor pathology.
| All (n) | RCC | LCC | p | |
|---|---|---|---|---|
| Tumor histology | 0.06 | |||
| Adenocarcinoma | 372 (93.5%) | 181 (91%) | 191 (96%) | |
| Mucinous carcinoma | 23 (5.8%) | 15 (7.5%) | 8 (4%) | |
| Others | 3 (0.8%) | 3 (1.5%) | 0 | |
| Lymph nodes isolated | <0.001 | |||
| <12 | 59 (14.9%) | 18 (9.1%) | 41 (20.6%) | |
| 12 | 338 (85.1%) | 180 (90.9%) | 158 (79.4%) | |
| Positive lymph nodes | 0.857 | |||
| Yes | 128 (43.1%) | 63 (31.8%) | 65 (32.7%) | |
| No | 169 (56.9%) | 135 (68.2%) | 134 (67.3%) | |
| Stage | 0.35 | |||
| Local (I–IIa) | 244 (61.3%) | 127 (63.8%) | 117 (58.8%) | |
| Advanced (>IIb) | 154 (38.7%) | 72 (36.2%) | 82 (41.2%) | |
| Specific Staging | 0.71 | |||
| I | 101 (25.4%) | 53 (26.6%) | 48 (24.1%) | |
| IIa | 142 (35.7%) | 74 (37.2%) | 68 (32.2%) | |
| IIb | 9 (2.3%) | 3 (1.5%) | 6 (3%) | |
| IIc | 7 (1.8%) | 3 (1.5%) | 4 (2%) | |
| IIIa | 15 (3.8%) | 6 (3%) | 9 (4.5%) | |
| IIIb | 67 (16.8%) | 34 (17.1%) | 33 (16.5%) | |
| IIIc | 22 (5.5%) | 13 (6.5%) | 9 (4.5%) | |
| IVa | 33 (8.3%) | 12 (6%) | 21 (10.6%) | |
| IVb | 2 (0.5%) | 1 (0.5%) | 1 (0.5%) |